Skip to main content

pentostatin

Generic: PENTOSTATIN·Brand: NIPENT, Nipent, PENTOSTATIN

pentostatin: 3 clinical trials tracked.

pentostatin evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pentostatin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Clinical Trial Registry Records (3)

A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Severe Aplastic Anemia Patients With COH-MC-17: A Non-Myeloablative/ Reduced-Intensity, Conditioning Regimen and CD4+ T-Cell-Depleted Haploidentical Hematopoietic Transplant

NCT05757310Registry updated 2026-01-05·Phase 1
Recruiting

Primary endpoint: Incidence of adverse events

Interventionalopen6 targetStarted 2024-11Completion 2027-061 site · United StatesCity of Hope Medical Center

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)

NCT03112603Registry updated 2025-08-12·Phase 3·INCY
Completed

Primary endpoint: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit

InterventionalRandomizedopen330 enrolledStarted 2017-06Completion 2022-1250 sites · Australia, Austria, Belgium, United StatesIncyte Corporation

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

NCT03077542Registry updated 2026-04-23·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Percentage of Participants Who Have Not Rejected Their Stem Cell Graft and Who Are Without Severe Graft-versus-host Disease Following Stem Cell Transplant

Interventionalopen57 targetStarted 2017-04Completion 2026-081 site · United StatesNational Heart, Lung, and Blood Institute (NHLBI)